[1] Nakatani T, Sase K, Oshiyama H, Akiyama M, Horie M, Nawata K, et al. Japanese registry for mechanically assisted circulatory support: first report. J Heart Lung Transplant 2017;36:1087-96.
[2] Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant 2015;34:1495-504.
[3] Kinugawa K, Nishimura T, Toda K, Saiki Y, Niinami H, Nunoda S, et al. The second official report from Japanese registry for mechanical assisted circulatory support (J-MACS): first results of bridge to bridge strategy. Gen Thorac Cardiovasc Surg 2020;68:102-11.
[4] Yoshitake S, Kinoshita O, Nawata K, Hoshino Y, Itoda Y, Kimura M, et al. Single-center experience of the bridge-to-bridge strategy using the Nipro paracorporeal ventricular assist device. J Artif Organs 2018;21:405-11.
[5] Yoshioka D, Takayama H, Garan AR, Topkara VK, Han J, Li B, et al. Bridge to durable left ventricular assist device for refractory cardiogenic shock. J Thorac Cardiovasc Surg 2017;153:752-62.e5.
[6] Takayama H, Soni L, Kalesan B, Truby LK, Ota T, Cedola S, et al. Bridge-to-decision therapy with a continuous-flow external ventricular assist device in refractory cardiogenic shock of various causes. Circ Heart Fail 2014;7:799-806.
[7] Heuman DM, Mihas AA, Habib A, Gilles HS, Stravitz RT, Sanyal AJ, et al. MELD-XI: a rational approach to “sickest first” liver transplantation in cirrhotic patients requiring anticoagulant therapy. Liver Transpl 2007;13:30-7.
[8] Fukushima N, Tatsumi E, Seguchi O, Takewa Y, Hamasaki T, Onda K, et al. Assessment of safety and effectiveness of the extracorporeal continuous-flow ventricular assist device (BR16010) use as a bridge-to-decision therapy for severe heart failure or refractory cardiogenic shock: study protocol for single-arm non-randomized, uncontrolled, and investigator-initiated clinical trial. Cardiovasc Drugs Ther 2018;32:373-9.
[9] Seguchi O, Fujita T, Watanabe T, Kuroda K, Hisamatsu E, Nakajima S, et al. Temporary biventricular support with extracorporeal membrane oxygenation: a feasible therapeutic approach for cardiogenic shock with multiple organ failure. J Artif Organs 2017;20:206-14.
[10] Suwa H, Seguchi O, Fujita T, Murata Y, Hieda M, Watanabe T, et al. Paracorporeal ventricular assist device as a bridge to transplant candidacy in the era of implantable continuous-flow ventricular assist device. J Artif Organs 2014;17:16-22.
[11] Toda K, Fujita T, Kobayashi J, Shimahara Y, Kitamura S, Seguchi O, et al. Impact of preoperative percutaneous cardiopulmonary support on outcome following left ventricular assist device implantation. Circ J 2012;76:88-95.
[12] Sandner SE, Zimpfer D, Zrunek P, Rajek A, Schima H, Dunkler D, et al. Renal function and outcome after continuous flow left ventricular assist device implantation. Ann Thorac Surg 2009;87:1072-8.
[13] Kirklin JK, Naftel DC, Kormos RL, Pagani FD, Myers SL, Stevenson LW, et al. Quantifying the effect of cardiorenal syndrome on mortality after left ventricular assist device implant. J Heart Lung Transplant 2013;32:1205-13.
[14] Cowger J, Sundareswaran K, Rogers JG, Park SJ, Pagani FD, Bhat G, et al. Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score. J Am Coll Cardiol 2013;61:313-21.
[15] Wadia Y, Etheridge W, Smart F, Wood RP, Frazier OH. Pathophysiology of hepatic dysfunction and intrahepatic cholestasis in heart failure and after left ventricular assist device support. J Heart Lung Transplant 2005;24:361-70.
[16] Matthews JC, Pagani FD, Haft JW, Koelling TM, Naftel DC, Aaronson KD. Model for end-stage liver disease score predicts left ventricular assist device operative transfusion requirements, morbidity, and mortality. Circulation 2010;121:214-20.
[17] Ton VK, Xie R, Hernandez-Montfort JA, Meyns B, Nakatani T, Yanase M, et al. Short- and long-term adverse events in patients on temporary circulatory support before durable ventricular assist device: an IMACS registry analysis. J Heart Lung Transplant 2020;39:342-52.
[18] Hernandez-Montfort JA, Xie R, Ton VK, Meyns B, Nakatani T, Yanase M, et al. Longitudinal impact of temporary mechanical circulatory support on durable ventricular assist device outcomes: an IMACS registry propensity matched analysis. J Heart Lung Transplant 2020;39:145-56.
[19] Nakamura M, Imamura T, Ueno H, Kinugawa K. Current indication and practical management of percutaneous left ventricular assist device support therapy in Japan. J Cardiol 2020;75:228-32.
[20] Sponga S, Benedetti G, Livi U. Short-term mechanical circulatory support as bridge to heart transplantation: paracorporeal ventricular assist device as alternative to extracorporeal life support. Ann Cardiothorac Surg 2019;8:143-50.
[21] Jasseron C, Lebreton G, Cantrelle C, Legeai C, Leprince P, Flecher E, et al. Impact of heart transplantation on survival in patients on venoarterial extracorporeal membrane oxygenation at listing in France. Transplantation 2016;100:1979-87.
[22] Hong KN, Iribarne A, Worku B, Takayama H, Gelijns AC, Naka Y, et al. Who is the high-risk recipient? Predicting mortality after heart transplant using pretransplant donor and recipient risk factors. Ann Thorac Surg 2011;92:520-7.
[23] Singh TP, Almond CS, Semigran MJ, Piercey G, Gauvreau K. Risk prediction for early in-hospital mortality following heart transplantation in the United States. Circ Heart Fail 2012;5:259-66.
[24] Weiss ES, Allen JG, Arnaoutakis GJ, George TJ, Russell SD, Shah AS, et al. Creation of a quantitative recipient risk index for mortality predication after cardiac transplantation (IMPACT). Ann Thorac Surg 2011;92:914-21.